<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920097</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00243141</org_study_id>
    <secondary_id>1R01CA245054-01A1</secondary_id>
    <nct_id>NCT04920097</nct_id>
  </id_info>
  <brief_title>Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy</brief_title>
  <official_title>Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed randomized control trial will evaluate auricular point acupressure (APA) on&#xD;
      chemotherapy-induced neuropathy (CIN), rigorously considering point specificity and placebo&#xD;
      effects by integrating self-report measures, psychophysical measures (QST), endogenous&#xD;
      biomarkers (cytokines), and neuro-imaging to investigate APA's efficacy and underlying&#xD;
      mechanism(s).&#xD;
&#xD;
      The investigators will use a randomized control trial, three-group design: (1) APA Group, (2)&#xD;
      Sham APA Control, and (3) Usual Care Control. A smartphone application for ecological&#xD;
      momentary assessment (EMA) will be used to monitor APA adherence and capture momentary CIN&#xD;
      severity and analgesic use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy-induced neuropathy (CIN)-pain, numbness, or tingling distributed in the hands&#xD;
      and feet-produces persistent symptoms affecting sensation and balance in cancer survivors. Up&#xD;
      to 50% of cancer survivors still suffer CIN 6 years after treatment. Duloxetine, the only&#xD;
      recommended drug by the American Society of Clinical Oncology, was found to be superior to&#xD;
      placebo but improved CIN by only 0.73 points (0-10 scale). No effective treatment for CIN has&#xD;
      been established except exercise, with an effect size of &lt;0.508. Opioids relieve CIN pain,&#xD;
      but long-term use is strongly discouraged due to opioid overuse.&#xD;
&#xD;
      The investigators propose to test auricular point acupressure (APA), an innovative and&#xD;
      scalable solution developed from auricular acupuncture. APA is a non-invasive (needleless)&#xD;
      and active treatment for patients with pain, whereas acupuncture is an invasive (using&#xD;
      needles) and passive treatment (administered by a licensed practitioner). In APA, small seeds&#xD;
      are taped on specific ear points by a skilled provider and patients press on the seeds to&#xD;
      stimulate ear points three times daily, three minutes per time, for a total of nine minutes&#xD;
      per day. APA provides pain relief within 1-2 minutes after ear stimulation and sustains pain&#xD;
      relief for one month after a 4-week APA intervention. APA is popular in Taiwan, China, and&#xD;
      Europe. Though its use is sparse in the U.S., a limited number of clinical trials have&#xD;
      supported APA in pain management.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>This prospective randomized controlled study will randomly assign participants into three groups: (1) APA Group (Self-Learn APA), (2) In-Person Group (In person training), and (3) Usual Care Control. During intervention phase, participants in the APA and In-Person groups will receive four in-person seed placement with weekly cycles, while Usual Care Group will receive counseling related how to self-manage their CIN to control time and attention. Participants in Usual Care will be re-randomized to APA or In-Person groups after completion of the study assessment. This proposed trial will evaluate the APA sustained effects for CIN up to a 3-month follow-up. The data will be collected at pre-intervention (T1), post-completion of the 4-week APA treatment (T2), and follow-ups at monthly post-completion of treatment for 3 months (T3-T5), for a total of 5 assessments. The primary endpoint is at 1-month follow-up.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants cannot be masked to the three treatment groups. The PI and Co-Is will be blinded regarding group assignment and will not contact or interact with the participants during the intervention and outcome assessments. Data collector for outcome assessments will be blinded since there will be no seeds placed on the ears when the data are collected.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain severity as assessed by the Brief Pain Inventory</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Pain severity will be assessed using the revised Brief Pain Inventory (BPI). The scale ranges from 0 (no pain) to 10 (severe pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in numbness as assessed by the Brief Pain Inventory</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Numbness will be assessed using the revised Brief Pain Inventory (BPI). The scale ranges from 0 (no numbness) to 10 (severe numbness).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in tingling as assessed by the Brief Pain Inventory</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Tingling will be assessed using the revised Brief Pain Inventory (BPI). The scale ranges from 0 (no tingling) to 10 (severe tingling).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in physical function as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) 29</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Physical function will be assessed using the subscale of physical function, Patient-Reported Outcomes Measurement Information System (PROMIS) 29. The subscale of physical function has a range of 5 (unable to function) to 20 (able to function without difficulty).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of pain sensitivity as assessed by Qualitative Sensory Testing (QST)</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Pain sensitivity will be measured by QST. The QST battery consists of light touch sensation as assessed by the Semmes-Weinstein Monofilament Test (SWMT), threshold and tolerance, temporal summation, and conditioned pain modulation (CPM). The threshold responses will be conducted in randomized and counterbalanced order; CPM will always occur last. Temporal summation measures, CPM, and after-sensation responses to these measures will be combined to create the central sensitization index for use in statistical analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of brain activity as assessed by fMRI Neuroimaging</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>All Functional magnetic resonance imaging (fMRIs) will be acquired on a 3.0 Tesla Siemens Prisma System (Siemens Medical Solutions, Erlangen, Germany) at The Johns Hopkins Hospital Radiology Building, Baltimore. Blood Oxygen Level Dependent functional images will be acquired using 2D gradient echo echo-planar imaging to cover the whole head [repetition time (TR)=2000ms, echo time (TE)=30ms, flip angle 90 degrees, acquisition matrix 64x64x40, slice thickness 4mm]; 300 volumes will be acquired for each fMRI data point. All imaging systems are connected to the hospital picture archiving and communication system. Each scan will take approximately 20 minutes.&#xD;
The investigator will report the functional connectivity networks of the Pearson correlation coefficient which ranges from 0 (no correlation) to 100 (perfect correlation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anti-inflammatory cytokines as assessed by serum cytokine biomarkers</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>A 15-mL blood sample will be drawn at each time point and blood samples will be collected using standard phlebotomy procedures and will be transferred and processed at the Johns Hopkins School of Nursing (JHSON) basic science laboratory (coagulation and serum separation by centrifugation). Serum will be stored at -80 Â°C at the JHSON. Once the study collection is completed, a panel of cytokines will be measured in diluted samples using the bio-plex pro-human chemokine panel.&#xD;
The investigator will report the number of participants that have a change in any anti-inflammatory cytokines level greater than 50 percent of baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pro-inflammatory cytokines as assessed by serum cytokine biomarkers</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>A 15-mL blood sample will be drawn at each time point and blood samples will be collected using standard phlebotomy procedures and will be transferred and processed at the Johns Hopkins School of Nursing (JHSON) basic science laboratory (coagulation and serum separation by centrifugation). Serum will be stored at -80 Â°C at the JHSON. Once the study collection is completed, a panel of cytokines will be measured in diluted samples using the bio-plex pro-human chemokine panel.&#xD;
The investigator will report the number of participants that have a change in any pro-inflammatory cytokine level greater than 50 percent of baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Chemotherapy-induced Neuropathy</condition>
  <arm_group>
    <arm_group_label>APA Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A self-guided smartphone application to self-administered APA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Virtual APA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A virtual APA (vAPA): APA app+ plus secure zoom sessions for APA coaching with questions and answers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wait-List Usual Care Control (UC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Virtual Auricular Point Acupressure (APA)</intervention_name>
    <description>Participants will learn how to self-administer APA by themselves.</description>
    <arm_group_label>APA Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>In-Person Training</intervention_name>
    <description>Participants will receive in-person training to self-administer APA.</description>
    <arm_group_label>Virtual APA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Participants will continue to do whatever they are receiving from their oncologist.</description>
    <arm_group_label>Usual Care Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  cancer patients ages â¥18 years&#xD;
&#xD;
          -  have received a medication in one of the following categories: platinum-based, vinca&#xD;
             alkaloids, bortezomib, eribulin, and/or taxanes&#xD;
&#xD;
          -  have completed their course of chemotherapy three months or more before enrollment&#xD;
&#xD;
          -  have CIN due to receiving neurotoxic chemotherapy for cancer or have pre-existing&#xD;
             peripheral neuropathy of another etiology that worsened after chemotherapy&#xD;
&#xD;
          -  have one of the average intensity of pain, or numbness, or tingling on their&#xD;
             extremities the previous week due to CIN â¥ 4 on a 11-point numerical scale.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  use of an investigational agent for pain control concurrently or within the past 30&#xD;
             days&#xD;
&#xD;
          -  use of an implantable drug delivery system, e.g. Medtronic SynchroMedÂ®&#xD;
&#xD;
          -  prior celiac plexus block or other neurolytic pain control treatment&#xD;
&#xD;
          -  other identified causes of painful paresthesia existing prior to chemotherapy (e.g.,&#xD;
             radiation or malignant plexopathy, lumbar or cervical radiculopathy,)&#xD;
&#xD;
          -  allergy to latex (the tapes for the APA include latex).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Smith, MD</last_name>
    <phone>(410)955-2091</phone>
    <email>tsmit136@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins School of Nursing</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao H Yeh</last_name>
      <phone>410-502-0184</phone>
      <email>cyeh13@jhu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ, Staff NP. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):636-641. doi: 10.1136/jnnp-2017-317215. Epub 2018 Feb 8.</citation>
    <PMID>29439162</PMID>
  </reference>
  <reference>
    <citation>Park SB. Chemotherapy-induced peripheral neuropathy: highlighting unmet needs. J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):558. doi: 10.1136/jnnp-2017-317528. Epub 2018 Feb 20.</citation>
    <PMID>29463571</PMID>
  </reference>
  <reference>
    <citation>Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017 Jun;81(6):772-781. doi: 10.1002/ana.24951. Epub 2017 Jun 5. Review.</citation>
    <PMID>28486769</PMID>
  </reference>
  <reference>
    <citation>Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014 Dec;155(12):2461-2470. doi: 10.1016/j.pain.2014.09.020. Epub 2014 Sep 23. Review.</citation>
    <PMID>25261162</PMID>
  </reference>
  <reference>
    <citation>Miaskowski C, Mastick J, Paul SM, Abrams G, Cheung S, Sabes JH, Kober KM, Schumacher M, Conley YP, Topp K, Smoot B, Mausisa G, Mazor M, Wallhagen M, Levine JD. Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life. J Cancer Surviv. 2018 Apr;12(2):234-245. doi: 10.1007/s11764-017-0662-8. Epub 2017 Nov 20.</citation>
    <PMID>29159795</PMID>
  </reference>
  <reference>
    <citation>Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL; American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jun 20;32(18):1941-67. doi: 10.1200/JCO.2013.54.0914. Epub 2014 Apr 14. Review.</citation>
    <PMID>24733808</PMID>
  </reference>
  <reference>
    <citation>Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013 Apr 3;309(13):1359-67. doi: 10.1001/jama.2013.2813.</citation>
    <PMID>23549581</PMID>
  </reference>
  <reference>
    <citation>Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, Fung C, Janelsins MC, Asare M, Lin PJ, Reddy PS, Giguere J, Berenberg J, Kesler SR, Mustian KM. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer. 2018 Apr;26(4):1019-1028. doi: 10.1007/s00520-017-4013-0. Epub 2017 Dec 14.</citation>
    <PMID>29243164</PMID>
  </reference>
  <reference>
    <citation>Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005 Mar 31;352(13):1324-34.</citation>
    <PMID>15800228</PMID>
  </reference>
  <reference>
    <citation>Gilron I, Tu D, Holden RR, Jackson AC, DuMerton-Shore D. Combination of morphine with nortriptyline for neuropathic pain. Pain. 2015 Aug;156(8):1440-1448. doi: 10.1097/j.pain.0000000000000149.</citation>
    <PMID>25749306</PMID>
  </reference>
  <reference>
    <citation>Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016 Apr 19;315(15):1624-45. doi: 10.1001/jama.2016.1464. Review.</citation>
    <PMID>26977696</PMID>
  </reference>
  <reference>
    <citation>Yeh CH, Lukkahatai N, Campbell C, Sair H, Zhang F, Mensah S, Garry C, Zeng J, Chen C, Pinedo M, Khoshnoodi M, Smith TJ, Saligan LN. Preliminary Effectiveness of Auricular Point Acupressure on Chemotherapy-Induced Neuropathy: Part 1 Self-Reported Outcomes. Pain Manag Nurs. 2019 Dec;20(6):614-622. doi: 10.1016/j.pmn.2019.04.005. Epub 2019 May 30.</citation>
    <PMID>31155279</PMID>
  </reference>
  <reference>
    <citation>Yeh CH, Lin WC, Kwai-Ping Suen L, Park NJ, Wood LJ, van Londen GJ, Howard Bovbjerg D. Auricular Point Acupressure to Manage Aromatase Inhibitor-Induced Arthralgia in Postmenopausal Breast Cancer Survivors: A Pilot Study. Oncol Nurs Forum. 2017 Jul 1;44(4):476-487. doi: 10.1188/17.ONF.476-487.</citation>
    <PMID>28632237</PMID>
  </reference>
  <reference>
    <citation>Yeh CH, Kwai-Ping Suen L, Chien LC, Margolis L, Liang Z, Glick RM, Morone NE. Day-to-Day Changes of Auricular Point Acupressure to Manage Chronic Low Back Pain: A 29-day Randomized Controlled Study. Pain Med. 2015 Oct;16(10):1857-69. doi: 10.1111/pme.12789. Epub 2015 May 19.</citation>
    <PMID>25988270</PMID>
  </reference>
  <reference>
    <citation>Yeh CH, Morone NE, Chien LC, Cao Y, Lu H, Shen J, Margolis L, Bhatnagar S, Hoffman S, Liang Z, Glick RM, Suen LK. Auricular point acupressure to manage chronic low back pain in older adults: a randomized controlled pilot study. Evid Based Complement Alternat Med. 2014;2014:375173. doi: 10.1155/2014/375173. Epub 2014 Jul 24.</citation>
    <PMID>25147574</PMID>
  </reference>
  <reference>
    <citation>Yeh CH, Chien LC, Balaban D, Sponberg R, Primavera J, Morone NE, Glick R, Albers KM, Cohen SM, Ren D, Huang LC, Suen LK. A randomized clinical trial of auricular point acupressure for chronic low back pain: a feasibility study. Evid Based Complement Alternat Med. 2013;2013:196978. doi: 10.1155/2013/196978. Epub 2013 Feb 28.</citation>
    <PMID>23554825</PMID>
  </reference>
  <reference>
    <citation>Yeh CH, Chien LC, Chiang YC, Huang LC. Auricular point acupressure for chronic low back pain: a feasibility study for 1-week treatment. Evid Based Complement Alternat Med. 2012;2012:383257. doi: 10.1155/2012/383257. Epub 2012 Jul 1.</citation>
    <PMID>22811745</PMID>
  </reference>
  <reference>
    <citation>Yeh CH, Chien LC, Chiang YC, Ren D, Suen LK. Auricular point acupressure as an adjunct analgesic treatment for cancer patients: a feasibility study. Pain Manag Nurs. 2015 Jun;16(3):285-93. doi: 10.1016/j.pmn.2014.08.005. Epub 2014 Oct 31.</citation>
    <PMID>25439120</PMID>
  </reference>
  <reference>
    <citation>Yeh CH, Chien LC, Lin WC, Bovbjerg DH, van Londen GJ. Pilot Randomized Controlled Trial of Auricular Point Acupressure to Manage Symptom Clusters of Pain, Fatigue, and Disturbed Sleep in Breast Cancer Patients. Cancer Nurs. 2016 Sep-Oct;39(5):402-10. doi: 10.1097/NCC.0000000000000303.</citation>
    <PMID>26390073</PMID>
  </reference>
  <reference>
    <citation>Yeh CH, Lukkahatai N, Campbell C, Sair H, Zhang F, Mensah S, Garry C, Zeng J, Chen C, Pinedo M, Khoshnoodi M, Perrin N, Smith TJ, Saligan LN. Preliminary Effectiveness of Auricular Point Acupressure on Chemotherapy-Induced Neuropathy: Part 2 Laboratory-Assessed and Objective Outcomes. Pain Manag Nurs. 2019 Dec;20(6):623-632. doi: 10.1016/j.pmn.2019.04.004. Epub 2019 Jun 14.</citation>
    <PMID>31204029</PMID>
  </reference>
  <reference>
    <citation>Yeh CH, Chiang YC, Hoffman SL, Liang Z, Klem ML, Tam WW, Chien LC, Suen LK. Efficacy of auricular therapy for pain management: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2014;2014:934670. doi: 10.1155/2014/934670. Epub 2014 Jul 23. Review.</citation>
    <PMID>25165482</PMID>
  </reference>
  <reference>
    <citation>Asher GN, Jonas DE, Coeytaux RR, Reilly AC, Loh YL, Motsinger-Reif AA, Winham SJ. Auriculotherapy for pain management: a systematic review and meta-analysis of randomized controlled trials. J Altern Complement Med. 2010 Oct;16(10):1097-108. doi: 10.1089/acm.2009.0451. Review.</citation>
    <PMID>20954963</PMID>
  </reference>
  <reference>
    <citation>Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001 Nov;94(2):149-158. doi: 10.1016/S0304-3959(01)00349-9.</citation>
    <PMID>11690728</PMID>
  </reference>
  <reference>
    <citation>Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008 Feb;9(2):105-21. Epub 2007 Dec 11.</citation>
    <PMID>18055266</PMID>
  </reference>
  <reference>
    <citation>Sisignano M, Baron R, Scholich K, Geisslinger G. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. Nat Rev Neurol. 2014 Dec;10(12):694-707. doi: 10.1038/nrneurol.2014.211. Epub 2014 Nov 4. Review.</citation>
    <PMID>25366108</PMID>
  </reference>
  <reference>
    <citation>Smith EM, Bridges CM, Kanzawa G, Knoerl R, Kelly JP 4th, Berezovsky A, Woo C. Cancer treatment-related neuropathic pain syndromes--epidemiology and treatment: an update. Curr Pain Headache Rep. 2014 Nov;18(11):459. doi: 10.1007/s11916-014-0459-7. Review.</citation>
    <PMID>25239766</PMID>
  </reference>
  <reference>
    <citation>Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract. 2012;2012:913848. doi: 10.1155/2012/913848. Epub 2012 Mar 14.</citation>
    <PMID>22482054</PMID>
  </reference>
  <reference>
    <citation>Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S. Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol. 2017 Aug 10;35(23):2604-2612. doi: 10.1200/JCO.2016.71.3552. Epub 2017 Jun 6.</citation>
    <PMID>28586243</PMID>
  </reference>
  <reference>
    <citation>Flatters SJL, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006 Jun;122(3):245-257. doi: 10.1016/j.pain.2006.01.037. Epub 2006 Mar 13.</citation>
    <PMID>16530964</PMID>
  </reference>
  <reference>
    <citation>Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1-32. doi: 10.1146/annurev.neuro.051508.135531. Review.</citation>
    <PMID>19400724</PMID>
  </reference>
  <reference>
    <citation>Janes K, Esposito E, Doyle T, Cuzzocrea S, Tosh DK, Jacobson KA, Salvemini D. A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. Pain. 2014 Dec;155(12):2560-2567. doi: 10.1016/j.pain.2014.09.016. Epub 2014 Sep 19.</citation>
    <PMID>25242567</PMID>
  </reference>
  <reference>
    <citation>Peters CM, Jimenez-Andrade JM, Kuskowski MA, Ghilardi JR, Mantyh PW. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res. 2007 Sep 7;1168:46-59. Epub 2007 Jul 17.</citation>
    <PMID>17698044</PMID>
  </reference>
  <reference>
    <citation>Ji XT, Qian NS, Zhang T, Li JM, Li XK, Wang P, Zhao DS, Huang G, Zhang L, Fei Z, Jia D, Niu L. Spinal astrocytic activation contributes to mechanical allodynia in a rat chemotherapy-induced neuropathic pain model. PLoS One. 2013 Apr 9;8(4):e60733. doi: 10.1371/journal.pone.0060733. Print 2013.</citation>
    <PMID>23585846</PMID>
  </reference>
  <reference>
    <citation>Tsavaris N, Kopterides P, Kosmas C, Efthymiou A, Skopelitis H, Dimitrakopoulos A, Pagouni E, Pikazis D, Zis PV, Koufos C. Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Med. 2008 Nov;9(8):1209-16. doi: 10.1111/j.1526-4637.2007.00325.x.</citation>
    <PMID>19067834</PMID>
  </reference>
  <reference>
    <citation>Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY; North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007 Nov 1;110(9):2110-8.</citation>
    <PMID>17853395</PMID>
  </reference>
  <reference>
    <citation>Magnowska M, IÅ¼ycka N, KapoÅa-CzyÅ¼ J, RomaÅa A, Lorek J, SpaczyÅski M, Nowak-Markwitz E. Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy. Ginekol Pol. 2018;89(4):200-4. doi: 10.5603/GP.a2018.0034.</citation>
    <PMID>29781075</PMID>
  </reference>
  <reference>
    <citation>Bellingham GA, Peng PW. Duloxetine: a review of its pharmacology and use in chronic pain management. Reg Anesth Pain Med. 2010 May-Jun;35(3):294-303. doi: 10.1097/AAP.0b013e3181df2645. Review.</citation>
    <PMID>20921842</PMID>
  </reference>
  <reference>
    <citation>Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015 Apr 1;33(10):1104-11. doi: 10.1200/JCO.2014.57.1547. Epub 2014 Dec 1.</citation>
    <PMID>25452437</PMID>
  </reference>
  <reference>
    <citation>Lu W, Giobbie-Hurder A, Freedman RA, Shin IH, Lin NU, Partridge AH, Rosenthal DS, Ligibel JA. Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial. Oncologist. 2020 Apr;25(4):310-318. doi: 10.1634/theoncologist.2019-0489. Epub 2019 Oct 14.</citation>
    <PMID>32297442</PMID>
  </reference>
  <reference>
    <citation>Li K, Giustini D, Seely D. A systematic review of acupuncture for chemotherapy-induced peripheral neuropathy. Curr Oncol. 2019 Apr;26(2):e147-e154. doi: 10.3747/co.26.4261. Epub 2019 Apr 1.</citation>
    <PMID>31043820</PMID>
  </reference>
  <reference>
    <citation>Franconi G, Manni L, SchrÃ¶der S, Marchetti P, Robinson N. A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy. Evid Based Complement Alternat Med. 2013;2013:516916. doi: 10.1155/2013/516916. Epub 2013 Jul 24.</citation>
    <PMID>23983788</PMID>
  </reference>
  <reference>
    <citation>Smith TJ, Razzak AR, Blackford AL, Ensminger J, Saiki C, Longo-Schoberlein D, Loprinzi CL. A Pilot Randomized Sham-Controlled Trial of MC5-A Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN). J Palliat Care. 2020 Jan;35(1):53-58. doi: 10.1177/0825859719827589. Epub 2019 Feb 3.</citation>
    <PMID>30714486</PMID>
  </reference>
  <reference>
    <citation>Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ, Lachance DH, Liu H, Shelerud RA, Cheville AL, Loprinzi CL. Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2015 Apr;23(4):943-51. doi: 10.1007/s00520-014-2424-8. Epub 2014 Sep 24.</citation>
    <PMID>25245776</PMID>
  </reference>
  <reference>
    <citation>Gewandter JS, Chaudari J, Ibegbu C, Kitt R, Serventi J, Burke J, Culakova E, Kolb N, Sluka KA, Tejani MA, Mohile NA. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. Support Care Cancer. 2019 May;27(5):1765-1774. doi: 10.1007/s00520-018-4424-6. Epub 2018 Aug 27.</citation>
    <PMID>30151681</PMID>
  </reference>
  <reference>
    <citation>Galantino ML, Brooks J, Tiger R, Jang S, Wilson K. Effectiveness of Somatic Yoga and Meditation: A Pilot Study in a Multicultural Cancer Survivor Population with Chemotherapy-Induced Peripheral Neuropathy. Int J Yoga Therap. 2020 Jan 1;30(1):49-61. doi: 10.17761/2020-D-18-00030.</citation>
    <PMID>31483689</PMID>
  </reference>
  <reference>
    <citation>Kono T, Mamiya N, Chisato N, Ebisawa Y, Yamazaki H, Watari J, Yamamoto Y, Suzuki S, Asama T, Kamiya K. Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med. 2011;2011:418481. doi: 10.1093/ecam/nep200. Epub 2011 Jan 11.</citation>
    <PMID>19952054</PMID>
  </reference>
  <reference>
    <citation>Li Y, Cui HJ, Huang JC, Wu XQ. Clinical study of Jiawei Huangqi Guizhi Wuwu Decoction in preventing and treating peripheral neuro-sensory toxicity caused by oxaliplatin. Chin J Integr Med. 2006 Mar;12(1):19-23.</citation>
    <PMID>16571278</PMID>
  </reference>
  <reference>
    <citation>Liu Y, May BH, Zhang AL, Guo X, Lu C, Xue CC, Zhang H. Integrative Herbal Medicine for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome in Colorectal Cancer: A Systematic Review and Meta-Analysis. Integr Cancer Ther. 2019 Jan-Dec;18:1534735418817833. doi: 10.1177/1534735418817833. Epub 2018 Dec 10.</citation>
    <PMID>30526124</PMID>
  </reference>
  <reference>
    <citation>Tofthagen C, Gonzalez L, Visovsky C, Akers A. Self-management of oxaliplatin-related peripheral neuropathy in colorectal cancer survivors. Chemother Res Pract. 2013;2013:547932. doi: 10.1155/2013/547932. Epub 2013 Aug 25.</citation>
    <PMID>24062949</PMID>
  </reference>
  <reference>
    <citation>Molsberger AF, Schneider T, Gotthardt H, Drabik A. German Randomized Acupuncture Trial for chronic shoulder pain (GRASP) - a pragmatic, controlled, patient-blinded, multi-centre trial in an outpatient care environment. Pain. 2010 Oct;151(1):146-154. doi: 10.1016/j.pain.2010.06.036. Epub 2010 Jul 23.</citation>
    <PMID>20655660</PMID>
  </reference>
  <reference>
    <citation>Nahin RL, Barnes PM, Stussman BJ. Insurance Coverage for Complementary Health Approaches Among Adult Users: United States, 2002 and 2012. NCHS Data Brief. 2016 Jan;(235):1-8.</citation>
    <PMID>26828643</PMID>
  </reference>
  <reference>
    <citation>Schapira MM, Mackenzie ER, Lam R, Casarett D, Seluzicki CM, Barg FK, Mao JJ. Breast cancer survivors willingness to participate in an acupuncture clinical trial: a qualitative study. Support Care Cancer. 2014 May;22(5):1207-15. doi: 10.1007/s00520-013-2073-3. Epub 2013 Dec 21.</citation>
    <PMID>24362843</PMID>
  </reference>
  <reference>
    <citation>Nogier P. Handbook to auriculotherapy. 1st ed. Moulins-les-Metz: Maisonneuve; 1981.</citation>
  </reference>
  <reference>
    <citation>Nogier R. How did Paul Nogier establish the map of the ear? Medical Acupuncture. 2014;26(2):76-83.</citation>
  </reference>
  <reference>
    <citation>Nogier P. Points Reflexes Auricularis. Maisonneuve SA: Moulin Les-Metz, France; 1987.</citation>
  </reference>
  <reference>
    <citation>Yeh CH, Huang LC. Comprehensive and systematic auricular diagnosis protocol. Medical Acupuncture 2013;25(6):423-436.</citation>
  </reference>
  <reference>
    <citation>Oleson T. Auriculotherapy Manual: Chinese and Western Systems of Ear Acupuncture. 4th ed. Edinburgh: Churchill Livingstone, Elsevier; 2014.</citation>
  </reference>
  <reference>
    <citation>Huang LC. Auricular Medicine: A Complete Manual of Auricular Diagnosis and Treatment. 1st ed. Orlando Florida: Auricular International Research &amp; Training; 2005.</citation>
  </reference>
  <reference>
    <citation>Alimi D, Geissmann A, Gardeur D. Auricular acupuncture stimulation measured on functional magnetic resonance imaging. Medical Acupuncture. 2002;13(2):18-21.</citation>
  </reference>
  <reference>
    <citation>Romoli M, Allais G, Airola G, Benedetto C, Mana O, Giacobbe M, Pugliese AM, Battistella G, Fornari E. Ear acupuncture and fMRI: a pilot study for assessing the specificity of auricular points. Neurol Sci. 2014 May;35 Suppl 1:189-93. doi: 10.1007/s10072-014-1768-7.</citation>
    <PMID>24867864</PMID>
  </reference>
  <reference>
    <citation>Keller M, Mazuch J, Abraham U, Eom GD, Herzog ED, Volk HD, Kramer A, Maier B. A circadian clock in macrophages controls inflammatory immune responses. Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21407-12. doi: 10.1073/pnas.0906361106. Epub 2009 Dec 1.</citation>
    <PMID>19955445</PMID>
  </reference>
  <reference>
    <citation>Fonken LK, Frank MG, Kitt MM, Barrientos RM, Watkins LR, Maier SF. Microglia inflammatory responses are controlled by an intrinsic circadian clock. Brain Behav Immun. 2015 Mar;45:171-9. doi: 10.1016/j.bbi.2014.11.009. Epub 2014 Nov 26.</citation>
    <PMID>25433170</PMID>
  </reference>
  <reference>
    <citation>Vickers AJ, Cronin AM, Maschino AC, Lewith G, MacPherson H, Foster NE, Sherman KJ, Witt CM, Linde K; Acupuncture Trialists' Collaboration. Acupuncture for chronic pain: individual patient data meta-analysis. Arch Intern Med. 2012 Oct 22;172(19):1444-53. doi: 10.1001/archinternmed.2012.3654. Review.</citation>
    <PMID>22965186</PMID>
  </reference>
  <reference>
    <citation>Vickers AJ, Vertosick EA, Lewith G, MacPherson H, Foster NE, Sherman KJ, Irnich D, Witt CM, Linde K; Acupuncture Trialists' Collaboration. Acupuncture for Chronic Pain: Update of an Individual Patient Data Meta-Analysis. J Pain. 2018 May;19(5):455-474. doi: 10.1016/j.jpain.2017.11.005. Epub 2017 Dec 2. Review.</citation>
    <PMID>29198932</PMID>
  </reference>
  <reference>
    <citation>Lundeberg T, Lund I. Acupuncture for preconditioning of expectancy and/or Pavlovian extinction. Acupunct Med. 2008 Dec;26(4):234-8. Review.</citation>
    <PMID>19098695</PMID>
  </reference>
  <reference>
    <citation>Lundeberg T, Lund I, NÃ¤slund J. Acupuncture--self-appraisal and the reward system. Acupunct Med. 2007 Sep;25(3):87-99. Review.</citation>
    <PMID>17906602</PMID>
  </reference>
  <reference>
    <citation>Furlan AD, Yazdi F, Tsertsvadze A, Gross A, Van Tulder M, Santaguida L, Gagnier J, Ammendolia C, Dryden T, Doucette S, Skidmore B, Daniel R, Ostermann T, Tsouros S. A systematic review and meta-analysis of efficacy, cost-effectiveness, and safety of selected complementary and alternative medicine for neck and low-back pain. Evid Based Complement Alternat Med. 2012;2012:953139. doi: 10.1155/2012/953139. Epub 2011 Nov 24.</citation>
    <PMID>22203884</PMID>
  </reference>
  <reference>
    <citation>Vickers AJ, Cronin AM, Maschino AC, Lewith G, Macpherson H, Victor N, Sherman KJ, Witt C, Linde K; Acupuncture Trialists' Collaboration. Individual patient data meta-analysis of acupuncture for chronic pain: protocol of the Acupuncture Trialists' Collaboration. Trials. 2010 Sep 28;11:90. doi: 10.1186/1745-6215-11-90.</citation>
    <PMID>20920180</PMID>
  </reference>
  <reference>
    <citation>Hsu C, Sherman KJ, Eaves ER, Turner JA, Cherkin DC, Cromp D, Schafer L, Ritenbaugh C. New perspectives on patient expectations of treatment outcomes: results from qualitative interviews with patients seeking complementary and alternative medicine treatments for chronic low back pain. BMC Complement Altern Med. 2014 Jul 30;14:276. doi: 10.1186/1472-6882-14-276.</citation>
    <PMID>25077732</PMID>
  </reference>
  <reference>
    <citation>Schafer LM, Hsu C, Eaves ER, Ritenbaugh C, Turner J, Cherkin DC, Sims C, Sherman KJ. Complementary and alternative medicine (CAM) providers' views of chronic low back pain patients' expectations of CAM therapies: a qualitative study. BMC Complement Altern Med. 2012 Nov 27;12:234. doi: 10.1186/1472-6882-12-234.</citation>
    <PMID>23186539</PMID>
  </reference>
  <reference>
    <citation>Schnur JB, Hallquist MN, Bovbjerg DH, Silverstein JH, Stojceska A, Montgomery GH. Predictors of expectancies for post-surgical pain and fatigue in breast cancer surgical patients. Pers Individ Dif. 2007;42(3):419-429.</citation>
    <PMID>19011695</PMID>
  </reference>
  <reference>
    <citation>Lind BK, Lafferty WE, Tyree PT, Sherman KJ, Deyo RA, Cherkin DC. The role of alternative medical providers for the outpatient treatment of insured patients with back pain. Spine (Phila Pa 1976). 2005 Jun 15;30(12):1454-9.</citation>
    <PMID>15959379</PMID>
  </reference>
  <reference>
    <citation>Shelton RC, Clarke Hillyer G, Hershman DL, Leoce N, Bovbjerg DH, Mandelblatt JS, Kushi LH, Lamerato L, Nathanson SD, Ambrosone CB, Neugut AI. Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study. Breast Cancer Res Treat. 2013 Feb;137(3):817-28. doi: 10.1007/s10549-012-2370-4. Epub 2012 Dec 22.</citation>
    <PMID>23263696</PMID>
  </reference>
  <reference>
    <citation>Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009 Dec;17(12):1483-91. doi: 10.1007/s00520-009-0613-7. Epub 2009 Mar 28.</citation>
    <PMID>19330359</PMID>
  </reference>
  <reference>
    <citation>Craig BM, Reeve BB, Brown PM, Cella D, Hays RD, Lipscomb J, Simon Pickard A, Revicki DA. US valuation of health outcomes measured using the PROMIS-29. Value Health. 2014 Dec;17(8):846-53. doi: 10.1016/j.jval.2014.09.005.</citation>
    <PMID>25498780</PMID>
  </reference>
  <reference>
    <citation>PROMIS-29 Profile v2. http://www.assessmentcenter.net/documents/InstrumentLibrary.pdf. Accessed July 31, 2015.</citation>
  </reference>
  <reference>
    <citation>(CMS) CfMMS. The 2019 Rate Announcement and Call Letter:and selecting &quot;2019 Announcement.&quot;. 2018; https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Announcements-and-Documents.html Accessed May 24, 2018.</citation>
  </reference>
  <reference>
    <citation>Campbell CM, Carroll CP, Kiley K, Han D, Haywood C Jr, Lanzkron S, Swedberg L, Edwards RR, Page GG, Haythornthwaite JA. Quantitative sensory testing and pain-evoked cytokine reactivity: comparison of patients with sickle cell disease to healthy matched controls. Pain. 2016 Apr;157(4):949-956. doi: 10.1097/j.pain.0000000000000473.</citation>
    <PMID>26713424</PMID>
  </reference>
  <reference>
    <citation>Yoo SS, Teh EK, Blinder RA, Jolesz FA. Modulation of cerebellar activities by acupuncture stimulation: evidence from fMRI study. Neuroimage. 2004 Jun;22(2):932-40.</citation>
    <PMID>15193624</PMID>
  </reference>
  <reference>
    <citation>Chen X, Spaeth RB, Freeman SG, Scarborough DM, Hashmi JA, Wey HY, Egorova N, Vangel M, Mao J, Wasan AD, Edwards RR, Gollub RL, Kong J. The modulation effect of longitudinal acupuncture on resting state functional connectivity in knee osteoarthritis patients. Mol Pain. 2015 Oct 29;11:67. doi: 10.1186/s12990-015-0071-9.</citation>
    <PMID>26511911</PMID>
  </reference>
  <reference>
    <citation>Yeh CH, Chien LC, Albers KM, et al. Function of auricular point acupressure in inducing changes in inflammatory cytokines during chronic low back pain: A pilot study. Medical Acupuncture. 2014;26(1):31-39.</citation>
  </reference>
  <reference>
    <citation>Agresti A. Categorical Data Analysis. 2nd ed. New Jersey: John Wiley &amp; Sons Inc.; 2002.</citation>
  </reference>
  <reference>
    <citation>Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. Springer Science &amp; Business Media; 2009.</citation>
  </reference>
  <reference>
    <citation>Xiang L, Tse SK, Lee AH. Influence diagnostics for generalized linear mixed models: applications to clustered data. Computational Statistics &amp; Data Analysis. 2002;40(4):759-774.</citation>
  </reference>
  <reference>
    <citation>Shrout PE, Bolger N. Mediation in experimental and nonexperimental studies: new procedures and recommendations. Psychol Methods. 2002 Dec;7(4):422-45.</citation>
    <PMID>12530702</PMID>
  </reference>
  <reference>
    <citation>Lin WC, Burke L, Schlenk EA, Yeh CH. Use of an Ecological Momentary Assessment Application to Assess the Effects of Auricular Point Acupressure for Chronic Low Back Pain. Comput Inform Nurs. 2019 May;37(5):276-282. doi: 10.1097/CIN.0000000000000478.</citation>
    <PMID>31094917</PMID>
  </reference>
  <reference>
    <citation>Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988 Dec;44(4):1049-60. Erratum in: Biometrics 1989 Mar;45(1):347.</citation>
    <PMID>3233245</PMID>
  </reference>
  <reference>
    <citation>Birhanu T, Molenberghs G, Sotto C, Kenward MG. Doubly robust and multiple-imputation-based generalized estimating equations. J Biopharm Stat. 2011 Mar;21(2):202-25. doi: 10.1080/10543406.2011.550096.</citation>
    <PMID>21390997</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

